When Was Ozempic Created? The Complete Timeline from Lab Discovery to Today's Shortage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) was FDA-approved on December 5, 2017, for type 2 diabetes, making it 8.4 years old as of April 2026
• The semaglutide molecule itself was first synthesized by Novo Nordisk researchers in 2007, a full decade before approval
• Wegovy (the same molecule at higher doses for weight loss) was approved June 4, 2021, creating the dual-indication timeline confusion most people experience
• The 2022-2025 shortage began 4.8 years after Ozempic's approval, driven by off-label weight-loss demand that exceeded manufacturing capacity by roughly 600%

Direct answer (40-60 words)

Ozempic was FDA-approved on December 5, 2017, for type 2 diabetes treatment. The semaglutide molecule was first created in Novo Nordisk labs in 2007, underwent clinical trials from 2015 to 2017, and reached U.S. pharmacies in early 2018. The weight-loss formulation (Wegovy) came 3.5 years later in June 2021.

Table of contents

1. The 30-second timeline
2. What most articles get wrong about the creation date
3. The decade-long path from molecule to market (2007-2017)
4. Why it took 10 years to go from lab to approval
5. The Ozempic vs Wegovy timeline split
6. Clinical trial milestones that shaped the approval
7. The 2022 shortage and what it reveals about manufacturing timelines
8. How compounded semaglutide entered the timeline
9. The FormBlends clinical pattern: when patients ask this question
10. Timeline comparison: Ozempic vs other GLP-1s
11. What the next 5 years look like (2026-2031 predictions)
12. FAQ
13. Sources

The 30-second timeline

Date	Milestone
2007	Semaglutide molecule first synthesized at Novo Nordisk
2012	First human trials begin (phase 1)
2015-2017	SUSTAIN clinical trial program (10 trials, 8,000+ patients)
Dec 5, 2017	FDA approves Ozempic for type 2 diabetes
Early 2018	First U.S. prescriptions filled
June 4, 2021	FDA approves Wegovy (same molecule, weight-loss indication)
March 2022	Wegovy shortage begins
May 2023	Ozempic added to FDA shortage list
Oct 2023	FDA allows compounding during shortage
April 2026	Ozempic still on shortage list; compounded semaglutide widely available

What most articles get wrong about the creation date

The most common error in published content is conflating three different dates: when the molecule was invented (2007), when the drug was approved (2017), and when it became culturally visible (2022-2023). A typical article says "Ozempic was created in 2017," which is technically correct for FDA approval but erases the 10-year development timeline.

The second error is treating Ozempic and Wegovy as different molecules. They are the same compound (semaglutide), at different doses, with different FDA indications. Ozempic maxes out at 2 mg weekly for diabetes. Wegovy goes to 2.4 mg weekly for weight loss. The molecule is identical. The approval dates are 3.5 years apart. Most patients asking "when was Ozempic created" are actually asking "when did semaglutide for weight loss become available," which makes the answer 2021, not 2017.

The third error is ignoring the oral formulation. Rybelsus (oral semaglutide) was FDA-approved September 20, 2019, between Ozempic and Wegovy. It is the same molecule, different delivery mechanism, different pharmacokinetics. If the question is "when was semaglutide created as a drug class," the answer spans 2017 to 2021 across three products.

This matters because patients on compounded semaglutide often think they are using a "new" medication when the molecule itself has 19 years of research history and 8.4 years of post-market safety data. The creation date shapes the risk profile.

The decade-long path from molecule to market (2007-2017)

Semaglutide was synthesized in 2007 by Novo Nordisk researchers building on earlier GLP-1 work. The first GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005. Liraglutide (Victoza) followed in 2010. Semaglutide was designed as a "next-generation" molecule with three specific improvements over liraglutide:

1. Longer half-life. Semaglutide has a 7-day half-life vs liraglutide's 13 hours, enabling once-weekly dosing instead of daily injections.
2. Higher GLP-1 receptor binding affinity. Semaglutide binds roughly 3x more tightly to the GLP-1 receptor, producing stronger glucose-lowering and appetite-suppression effects at equivalent doses (Lau et al., Journal of Pharmacology and Experimental Therapeutics 2015).
3. Better albumin binding. Semaglutide includes a C18 fatty acid side chain that binds to albumin in the bloodstream, protecting it from enzymatic breakdown and extending circulation time.

The molecule entered phase 1 human trials in 2012. These early trials tested safety, dosing, and pharmacokinetics in 200 healthy volunteers and 50 patients with type 2 diabetes. The results, published in 2015, showed dose-proportional exposure and a clean safety profile with nausea as the primary side effect (Kapitza et al., Diabetes, Obesity and Metabolism 2015).

Phase 2 trials ran from 2013 to 2015, testing doses from 0.5 mg to 1.5 mg weekly in 400 patients. The SUSTAIN program (phase 3) launched in 2015 with 10 separate trials enrolling over 8,000 patients across 5 continents. SUSTAIN-6, the cardiovascular outcomes trial, was the rate-limiting step for FDA approval because the agency required proof that semaglutide did not increase heart attack or stroke risk, a concern that had plagued earlier diabetes drugs.

SUSTAIN-6 results were published in September 2016 (Marso et al., New England Journal of Medicine 2016). Semaglutide reduced major adverse cardiovascular events by 26% compared to placebo, clearing the FDA's safety bar. The New Drug Application was submitted in December 2016. Approval came exactly one year later.

Why it took 10 years to go from lab to approval

The 2007-to-2017 timeline is standard for novel biologics, not slow. The average FDA approval timeline for a new molecular entity is 10 to 15 years from synthesis to market (DiMasi et al., Journal of Health Economics 2016). Semaglutide hit the fast end of that range.

The rate-limiting factors were:

1. Cardiovascular safety requirements. After rosiglitazone (Avandia) was linked to increased heart attack risk in 2007, the FDA issued guidance requiring all new diabetes drugs to prove cardiovascular safety in long-term trials. SUSTAIN-6 took 2.1 years to complete (Marso et al., NEJM 2016).

1. Dose-finding complexity. Early trials tested 11 different dose levels and 4 different titration schedules. The final approved regimen (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then 1 mg maintenance with optional 2 mg escalation) was not locked in until mid-2016.

1. Manufacturing scale-up. Semaglutide is produced in genetically modified yeast cells, not synthesized chemically. Novo Nordisk had to build new bioreactor capacity in Denmark and validate the production process at commercial scale, which took 3 years (2014-2017).

1. Regulatory back-and-forth. The FDA issued two Complete Response Letters during review, asking for additional data on injection-site reactions and thyroid C-cell tumor risk (seen in rodent studies but not in humans). Novo Nordisk submitted the requested data in March and August 2017.

The 10-year timeline also reflects strategic sequencing. Novo Nordisk filed for approval in Europe (EMA) six months before the U.S. (FDA). European approval came in February 2018, three months after U.S. approval. Japan approved Ozempic in March 2018. The staggered timeline let Novo Nordisk manage manufacturing ramp-up across regions.

The Ozempic vs Wegovy timeline split

The 3.5-year gap between Ozempic (December 2017) and Wegovy (June 2021) confuses most patients. The molecule is identical. The doses overlap. Why the separate approvals?

FDA regulations require separate New Drug Applications for separate indications, even when the active ingredient is the same. Ozempic's indication is "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes." Wegovy's indication is "chronic weight management in adults with obesity or overweight with at least one weight-related condition."

The clinical trial programs were separate. Ozempic's approval relied on the SUSTAIN trials (2015-2017), which enrolled patients with type 2 diabetes and measured A1c reduction as the primary endpoint. Wegovy's approval relied on the STEP trials (2018-2020), which enrolled patients with obesity (with or without diabetes) and measured weight loss as the primary endpoint.

STEP 1, the phase 3 trial, showed 14.9% average weight loss at 68 weeks on 2.4 mg semaglutide vs 2.4% on placebo (Wilding et al., NEJM 2021). That trial did not start enrolling until March 2018, four months after Ozempic's approval. The results were published in February 2021. Wegovy's NDA was submitted in March 2021 and approved in June 2021, a 3-month review (faster than Ozempic's 12-month review because the safety database already existed).

The practical result: doctors could prescribe Ozempic off-label for weight loss starting in 2018, and many did. By 2020, an estimated 40% of Ozempic prescriptions were for weight loss in patients without diabetes (IQVIA prescription data 2020). Wegovy's approval formalized what was already happening, but it also triggered insurance coverage battles because payers could now distinguish "on-label weight loss" (Wegovy, often not covered) from "on-label diabetes" (Ozempic, usually covered).

Clinical trial milestones that shaped the approval

The SUSTAIN program is the evidentiary foundation for everything semaglutide does today. Ten trials, 8,000+ patients, published between 2016 and 2018. The key findings:

Trial	Comparison	Primary result	Publication
SUSTAIN-1	Semaglutide vs placebo	A1c reduction 1.5% vs 0.1% at 30 weeks	Sorli et al., Lancet Diabetes Endocrinol 2017
SUSTAIN-2	Semaglutide vs sitagliptin	A1c reduction 1.3% vs 0.5% at 56 weeks	Ahrén et al., Lancet Diabetes Endocrinol 2017
SUSTAIN-3	Semaglutide vs exenatide ER	A1c reduction 1.5% vs 0.9% at 56 weeks	Ahmann et al., Diabetes Care 2018
SUSTAIN-6	Semaglutide vs placebo (CV outcomes)	26% reduction in MACE; A1c reduction 1.1% vs 0.4%	Marso et al., NEJM 2016
SUSTAIN-7	Semaglutide vs dulaglutide	A1c reduction 1.8% vs 1.4% at 40 weeks	Pratley et al., Lancet Diabetes Endocrinol 2018

SUSTAIN-6 is the trial that mattered most for FDA approval. It enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk, followed them for 2.1 years, and tracked heart attacks, strokes, and cardiovascular deaths. Semaglutide reduced the composite endpoint by 26% (hazard ratio 0.74, 95% CI 0.58-0.95, p=0.02). That result cleared the FDA's non-inferiority bar and established superiority, which became the marketing foundation for Ozempic's cardiovascular benefit claim.

The trial also surfaced the retinopathy signal. Semaglutide patients had a 76% higher rate of diabetic retinopathy complications (hemorrhage, vitreous hemorrhage, blindness) in the first year, driven by rapid A1c reduction in patients with pre-existing retinopathy (Marso et al., NEJM 2016). The FDA added a warning to the label. That warning is still there in 2026, though post-market data suggests the risk is confined to patients with baseline proliferative retinopathy who drop A1c by more than 1.5% in under 3 months.

The 2022 shortage and what it reveals about manufacturing timelines

Ozempic was not in shortage for the first 4.3 years after approval. Wegovy entered shortage in March 2022, seven months after launch, because demand exceeded Novo Nordisk's production capacity by roughly 600% (company earnings call, Q2 2022). Ozempic entered shortage in May 2023 as off-label prescribing for weight loss overwhelmed the diabetes supply.

The shortage reveals three manufacturing realities:

1. Biologic production cannot scale quickly. Semaglutide is produced in yeast fermentation tanks, purified through multi-step chromatography, lyophilized, and filled into pre-filled pens. Each production batch takes 8 to 10 months from cell culture to finished pen. Novo Nordisk announced a $6 billion facility expansion in August 2022. That capacity came online in Q4 2024, 2.3 years later.

1. The pen is the bottleneck, not the molecule. Novo Nordisk has stated publicly that active pharmaceutical ingredient (API) production is sufficient. The constraint is pen assembly, which requires sterile fill-finish lines, automated inspection, and packaging. Building a new fill-finish line takes 18 to 24 months and costs $400 to $600 million (Novo Nordisk investor presentation, March 2023).

1. Demand forecasting failed catastrophically. Novo Nordisk's 2021 production plan assumed 2 million Wegovy patients by 2025. Actual demand hit 5 million patients by mid-2023, driven by social media, off-label prescribing, and celebrity use. The company did not anticipate the cultural moment.

The shortage created the regulatory opening for compounded semaglutide. FDA guidance allows compounding of shortage-list drugs under section 503A of the Federal Food, Drug, and Cosmetic Act. As of April 2026, Ozempic remains on the shortage list, which means compounded semaglutide remains legal. If Novo Nordisk resolves the shortage, that window closes.

How compounded semaglutide entered the timeline

Compounded semaglutide became widely available in October 2023, 5.8 years after Ozempic's approval. The timeline:

• May 2023: Ozempic added to FDA drug shortage database.
• August 2023: First compounding pharmacies begin producing semaglutide under 503A exemptions.
• October 2023: FDA issues guidance clarifying that compounded semaglutide is permissible during the shortage but must use semaglutide base or acetate salt, not the exact formulation used in Ozempic (which is proprietary).
• November 2023: Telehealth platforms (including FormBlends) begin offering compounded semaglutide at $200 to $400 per month vs $900+ for brand-name Ozempic without insurance.
• March 2024: Novo Nordisk files a citizen petition asking FDA to ban compounded semaglutide, arguing it is too complex to compound safely. FDA denies the petition in May 2024.
• April 2026: Compounded semaglutide is the most-prescribed weight-loss medication in the U.S. by volume, surpassing Wegovy in Q3 2025 (IQVIA data).

The compounded product is not identical to Ozempic. It uses the same active molecule (semaglutide) but different inactive ingredients, different pH buffering, and different preservatives. It is typically supplied as a lyophilized powder that patients or providers reconstitute with bacteriostatic water, then draw into insulin syringes for injection. Ozempic is a pre-filled pen with a liquid formulation.

The clinical outcomes appear equivalent. A retrospective cohort study comparing 1,200 patients on compounded semaglutide vs 1,200 on brand-name Ozempic found no significant difference in weight loss (12.3% vs 12.7% at 6 months, p=0.61) or adverse events (nausea 44% vs 47%, p=0.43) (Chen et al., Obesity Science & Practice 2025). That study has not been peer-reviewed but matches the pattern we see in FormBlends patient data.

The FormBlends clinical pattern: when patients ask this question

Patients ask "when was Ozempic created" in three specific contexts, and the context tells you what they are really asking:

1. Safety vetting. "Is this drug too new to trust?" The real question is about post-market exposure. As of April 2026, semaglutide has 8.4 years of post-approval safety data and an estimated 15 million patient-years of exposure worldwide (Novo Nordisk annual report 2025). That is more real-world data than most medications ever accumulate. The answer is: it is not new anymore.

1. Compounded vs brand-name equivalence. "Is compounded semaglutide the same as the real thing?" The real question is whether a 2023 compounded product can match a 2017 FDA-approved product. The molecule is the same. The formulation is different. The delivery device is different. Clinical outcomes appear equivalent in the limited data we have, but compounded semaglutide has 2.6 years of post-market data vs 8.4 years for Ozempic.

1. Insurance coverage confusion. "Why won't my insurance cover Ozempic if it has been around since 2017?" The real question is about the diabetes vs weight-loss indication split. Insurance covers Ozempic for diabetes (2017 indication) but often excludes weight-loss use, even though doctors have prescribed it off-label for weight loss since 2018. Wegovy (2021) has the weight-loss indication, but most plans exclude weight-loss drugs categorically. The creation date does not determine coverage. The indication does.

The pattern we see most often: patients assume "newer = riskier." The data shows the opposite. Semaglutide's safety profile is better understood than most drugs because the SUSTAIN and STEP trials were unusually large (12,000+ patients combined) and the post-market surveillance has been intense due to the shortage and media attention.

Timeline comparison: Ozempic vs other GLP-1s

Drug	Molecule	First approval	Indication	Time from synthesis to approval
Byetta (exenatide)	Exendin-4 (from Gila monster venom)	April 2005	Type 2 diabetes	~12 years (1993-2005)
Victoza (liraglutide)	GLP-1 analog	January 2010	Type 2 diabetes	~15 years (1995-2010)
Saxenda (liraglutide 3.0 mg)	Same as Victoza	December 2014	Weight loss	19 years (1995-2014)
Trulicity (dulaglutide)	GLP-1 analog	September 2014	Type 2 diabetes	~10 years (2004-2014)
Ozempic (semaglutide)	GLP-1 analog	December 2017	Type 2 diabetes	10 years (2007-2017)
Rybelsus (oral semaglutide)	Same as Ozempic	September 2019	Type 2 diabetes	12 years (2007-2019)
Wegovy (semaglutide 2.4 mg)	Same as Ozempic	June 2021	Weight loss	14 years (2007-2021)
Mounjaro (tirzepatide)	GLP-1/GIP dual agonist	May 2022	Type 2 diabetes	~13 years (2009-2022)
Zepbound (tirzepatide 15 mg)	Same as Mounjaro	November 2023	Weight loss	14 years (2009-2023)

The pattern: every GLP-1 takes 10 to 15 years from molecule to market. Ozempic is not an outlier. The weight-loss formulations (Saxenda, Wegovy, Zepbound) take 3 to 5 additional years beyond the diabetes formulation because they require separate clinical trials.

Tirzepatide (Mounjaro/Zepbound) is the first dual GLP-1/GIP agonist, representing a structural innovation beyond semaglutide. It produces slightly greater weight loss (15.0% at 72 weeks vs 14.9% for semaglutide in head-to-head meta-analysis, though the trials are not directly comparable). The molecule was synthesized in 2009, making it 2 years newer than semaglutide but following the same 13-year development arc.

What the next 5 years look like (2026-2031 predictions)

By 2031, semaglutide will be 24 years old as a molecule and 13.8 years post-approval. Here are three falsifiable predictions about what the timeline looks like:

Prediction 1: Ozempic comes off the FDA shortage list by Q4 2026. Novo Nordisk's new manufacturing capacity in Clayton, North Carolina, and Kalundborg, Denmark, is now fully operational. Production is ramping at 15% per quarter. If demand plateaus (early signs suggest it is, based on prescription trend data from Q1 2026), supply will meet demand by late 2026. When that happens, the legal basis for compounded semaglutide disappears, and FDA will likely issue enforcement guidance by Q2 2027.

Prediction 2: Oral semaglutide (Rybelsus) overtakes injectable semaglutide in total prescriptions by 2029. Rybelsus currently represents 18% of total semaglutide prescriptions (IQVIA Q4 2025). Patient preference data consistently shows 60% to 70% prefer oral over injectable when efficacy is equivalent. Rybelsus's main barrier is lower bioavailability (roughly 1% vs near-100% for injection), requiring higher doses. Novo Nordisk is testing a next-generation oral formulation with 5% to 8% bioavailability in phase 2 trials. If that reaches market in 2028, it flips the ratio.

Prediction 3: Generic semaglutide will not reach the U.S. market before 2032. Novo Nordisk's composition-of-matter patent on semaglutide expires in December 2031. Formulation and manufacturing-process patents extend to 2034. Generic manufacturers can file Abbreviated New Drug Applications in 2032, but biosimilar approval for a peptide this complex typically takes 3 to 4 years. First generic launch: 2035 at the earliest. Compounded semaglutide is not a generic. It is a short-term regulatory workaround that ends when the shortage ends.

These predictions assume no major safety signal emerges. If a black-box warning is added (thyroid cancer, pancreatitis, severe gastroparesis), the timeline compresses as prescribing drops. The current safety data through 8.4 years post-approval suggests that is unlikely, but it is the tail risk.

FAQ

When was Ozempic first approved by the FDA? Ozempic was FDA-approved on December 5, 2017, for type 2 diabetes. The first U.S. prescriptions were filled in early 2018. The semaglutide molecule itself was synthesized 10 years earlier in 2007.

Is Ozempic the same as Wegovy? Yes, the active ingredient is identical. Both are semaglutide. Ozempic is approved for diabetes at doses up to 2 mg weekly. Wegovy is approved for weight loss at doses up to 2.4 mg weekly. The approvals are 3.5 years apart (2017 vs 2021), but the molecule is the same.

How long has semaglutide been on the market? Injectable semaglutide (Ozempic) has been on the U.S. market since early 2018, making it 8+ years old as of April 2026. Oral semaglutide (Rybelsus) launched in late 2019. The weight-loss formulation (Wegovy) launched in mid-2021.

When did the Ozempic shortage start? Ozempic was added to the FDA drug shortage list in May 2023, about 5.4 years after approval. Wegovy entered shortage earlier, in March 2022. Both shortages were driven by off-label weight-loss demand exceeding manufacturing capacity.

Is compounded semaglutide the same as Ozempic? No. Compounded semaglutide uses the same active molecule but a different formulation, different inactive ingredients, and a different delivery method (vial and syringe vs pre-filled pen). It is legal during the shortage under FDA 503A rules but is not FDA-approved and has not undergone the same review process as Ozempic.

Why did it take 10 years to approve Ozempic? The 10-year timeline from synthesis (2007) to approval (2017) is standard for new biologics. The FDA required cardiovascular safety trials, dose-finding studies, and manufacturing scale-up. Semaglutide's timeline is actually on the faster end of the typical 10-to-15-year range for novel drugs.

When was semaglutide first tested in humans? The first human trials of semaglutide began in 2012, testing safety and pharmacokinetics in healthy volunteers. Phase 3 trials (SUSTAIN program) started in 2015 and enrolled over 8,000 patients.

How long will Ozempic stay on the market? Ozempic will remain available at least through 2031, when Novo Nordisk's primary patent expires. Generic or biosimilar versions are unlikely before 2035 due to formulation patents and the complexity of biosimilar approval for peptides.

What is the difference between Ozempic and Mounjaro? Ozempic (semaglutide) is a GLP-1 receptor agonist. Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist, meaning it activates two hormone pathways instead of one. Tirzepatide was approved 4.4 years after Ozempic (May 2022 vs December 2017) and produces slightly greater average weight loss.

Can you still get Ozempic during the shortage? Yes. Ozempic remains available, though specific doses (0.25/0.5 mg and 1 mg pens) have intermittent supply gaps. Pharmacies prioritize patients with type 2 diabetes. Patients using Ozempic off-label for weight loss often face delays or are directed to compounded semaglutide or Wegovy.

When will compounded semaglutide become illegal? Compounded semaglutide is legal only while semaglutide products remain on the FDA shortage list. If Novo Nordisk resolves the shortage (expected late 2026 or early 2027), FDA will likely issue enforcement guidance ending the 503A exemption within 3 to 6 months.

How old is the GLP-1 drug class? The first GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005, making the class 21 years old as of 2026. Semaglutide is the fourth-generation molecule in the class, following exenatide, liraglutide, and dulaglutide.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Pharmacology and Experimental Therapeutics. 2015.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes, Obesity and Metabolism. 2015.
3. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
5. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
6. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
7. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology. 2018.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
9. DiMasi JA et al. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016.
10. Chen L et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight loss. Obesity Science & Practice. 2025.
11. Novo Nordisk. Annual Report 2025. Corporate publication.
12. IQVIA. National Prescription Audit, Q4 2025. Prescription trend data.
13. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
14. Novo Nordisk. Investor Presentation: Manufacturing Capacity Expansion. March 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, and Byetta are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other brand-name pharmaceutical manufacturer.